Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits
2009; Elsevier BV; Volume: 27; Issue: 17 Linguagem: Inglês
10.1016/j.vaccine.2009.01.127
ISSN1873-2518
AutoresAngelique G.S.C. Jansen, Gerwin D. Rodenburg, Sabine C. de Greeff, Eelko Hak, Reinier H. Veenhoven, Lodewijk Spanjaard, Leo M. Schouls, Elisabeth A. M. Sanders, Arie van der Ende,
Tópico(s)Respiratory viral infections research
ResumoWith a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for ∼25% of the Dutch population (1275 hospitalized cases) over the period June 2004–June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3–5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60–64-yr-olds to 97 cases per 100,000 in persons ≥90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy.
Referência(s)